ValiRx plc (LON:VAL – Get Free Report) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as GBX 3.23 ($0.04) and last traded at GBX 3.30 ($0.04), with a volume of 607805 shares traded. The stock had previously closed at GBX 3.45 ($0.04).
ValiRx Stock Up 1.5 %
The company has a current ratio of 13.37, a quick ratio of 1.27 and a debt-to-equity ratio of 0.73. The firm has a market capitalization of £4.43 million, a price-to-earnings ratio of -111.67 and a beta of 0.63. The stock has a fifty day moving average of GBX 3.78 and a 200-day moving average of GBX 6.56.
About ValiRx
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Further Reading
- Five stocks we like better than ValiRx
- What is a Stock Market Index and How Do You Use Them?
- MarketBeat Week in Review – 4/22 – 4/26
- Transportation Stocks Investing
- 3 Stocks Leading the U.S. Agriculture Comeback
- What Makes a Stock a Good Dividend Stock?
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
